IbogaineWiki

    Ibogaine News

    From Ibogaine Wiki, the free encyclopedia about ibogaine

    This portal collects recent news items in ibogaine research, clinical trials, policy, and treatment. Each entry links to relevant articles on Ibogaine Wiki for further reading.

    November 2026

    • Nov 12:The U.S. Department of Health and Human Services announced up to $4.9 million over five years through ARPA-H to prepare ibogaine for U.S. clinical trials in post-traumatic stress disorder, including in veterans, with teams led by Mark Cuban Cost Plus Drug Company and Beond.[1][2][3][4][5][6][7] See ARPA-H ibogaine awards.
    • Nov 12:Alongside the ARPA-H ibogaine awards, the National Institute of Mental Health opened a $20 million funding opportunity for a research network on rapid-acting psychotropic drugs such as ketamine, esketamine and psilocybin, with recipients expected in summer 2027. Some outlets reported the two programs together as about $25 million.[1][8][9]
    • Nov 12:Veterans organizations, including Iraq and Afghanistan Veterans of America, welcomed the HHS and VA announcement, and Americans for Ibogaine called for continued coordination between federal agencies on ibogaine research.[10][11]
    • Nov 9:The Drug Enforcement Administration proposed raising the legal U.S. production quota for ibogaine from 210 grams in 2026 to 12,002 grams in 2027, citing increased research and clinical trial activity for conditions such as PTSD and depression.[12] See Ibogaine Legal Status in the United States.

    October 2026

    • Oct 25:Politico reported that a senior VA health adviser wants to expand the VA's capacity to offer psychedelic therapy to as many as 2.1 million veterans with conditions such as PTSD or depression.[13]
    • Oct 5:The FDA requested public input on designing early-phase ibogaine clinical trials. HHS named adults with opioid use disorder and PTSD as the first priority groups for federally supported research, funded through ARPA-H and NIDA. Comments are open until November 20, 2026 (docket FDA-2026-N-10429).[14]

    August 2026

    • Aug 18:The University of Miami gave the federal government its original 1994 ibogaine Investigational New Drug (IND) application, which came out of research led in the 1990s by Deborah Mash.[15]

    July 2026

    • Jul:The FDA finalized its guidance "Psychedelic Drugs: Considerations for Clinical Investigations", and HHS and the VA announced a partnership to prepare the VA for future FDA-approved psychedelic therapies.[14]

    May 2026

    • May 14:Colorado's legislature passed HB 26-1325, authorizing up to five ibogaine research sites and bringing ibogaine into the state's natural medicine framework, effective August 12, 2026.[16]

    April 2026

    • Apr:Days after the executive order, the FDA allowed an early-phase clinical study of noribogaine hydrochloride, an ibogaine derivative, for alcohol use disorder.[17]
    • Apr 18:President Trump signed an executive order directing federal agencies to speed up review of psychedelic drugs, naming ibogaine specifically.[18]

    March 2026

    • Mar 26:Mississippi enacted House Bill 314, appropriating $5 million for an ibogaine research consortium aimed at advancing FDA approval.[19]
    • Mar 1:The New York Times Magazine publishes a feature on ibogaine as a psychedelic therapy, spotlighting its use in trauma recovery and PTSD.

    February 2026

    January 2026

    November 2025

    September 2025

    July 2025

    References

    1. U.S. Department of Health and Human Services. "HHS Announces ARPA-H Awards to Advance Ibogaine Development for PTSD & New $20 Million Funding Opportunity to Advance Rapid-acting Psychotropics." November 12, 2026. https://www.hhs.gov/press-room/hhs-advances-ibogaine-ptsd-research-rapid-acting-mental-health-treatments.html
    2. Associated Press via PBS NewsHour. "Trump administration officials announce PTSD research funding for psychedelic drug ibogaine." November 12, 2026. https://www.pbs.org/newshour/politics/watch-trump-administration-officials-announce-ptsd-research-funding-for-psychedelic-drug-ibogaine
    3. STAT News. "HHS plans funding for research into ibogaine for PTSD." November 13, 2026. https://www.statnews.com/2026/11/13/biotech-news-hhs-funding-for-research-into-ibogaine-for-ptsd/
    4. Forbes. "Balancing Promise And Risk: Trump Funds Ibogaine Studies On Vet PTSD." November 13, 2026. https://www.forbes.com/sites/joshuacohen/2026/11/13/balancing-promise-and-risk-white-house-funds-ibogaine-studies-for-veteran-ptsd/
    5. USA Today. "US backs study of psychedelic drug for veterans with PTSD. What is it?" November 12, 2026. https://www.usatoday.com/story/news/health/2026/11/12/psychedelic-drug-ibogaine-veterans-ptsd/92742526007/
    6. MedPage Today. "Trump Officials Will Fund New Research on Controversial Psychedelic Drug Ibogaine." November 2026. https://amp.medpagetoday.com/publichealthpolicy/washington-watch/123865
    7. Becker's Hospital Review. "Mark Cuban's Cost Plus to develop US-made ibogaine in HHS push." November 2026. https://www.beckershospitalreview.com/pharmacy/mark-cubans-cost-plus-to-develop-us-made-ibogaine-in-hhs-push/
    8. BioSpace. "HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran's Day." November 2026. https://www.biospace.com/drug-development/hhs-pumps-up-to-25m-into-ibogaine-other-psychotropic-drugs-on-veterans-day
    9. KFF Health News. "HHS Earmarks Nearly $25M For Research Into Psychedelics As Mental Health Treatment." November 13, 2026. https://kffhealthnews.org/morning-breakout/mental-health-111326/
    10. CBS4 / The National News Desk. "Veteran advocates welcome federal push to study psychoactive drug ibogaine for PTSD." November 12, 2026. https://mycbs4.com/news/nation-world/veteran-advocates-welcome-federal-push-to-study-psychoactive-drug-ibogaine-for-ptsd
    11. Americans for Ibogaine (FinanceWire, via Markets Insider). "Americans for Ibogaine Welcomes New Federal Investments in Ibogaine Research and Mental Health Treatment." November 13, 2026. https://markets.businessinsider.com/news/currencies/americans-for-ibogaine-welcomes-new-federal-investments-in-ibogaine-research-and-mental-health-treatment-1036758878
    12. Marijuana Moment. "DEA Boosts Psychedelic Production Quotas For 2027 While Previewing Separate Marijuana Proposal Under Rescheduling." November 9, 2026. https://www.marijuanamoment.net/dea-boosts-psychedelic-production-quotas-for-2027-while-previewing-separate-marijuana-proposal-under-rescheduling/
    13. Politico. "The Trump administration moves to treat millions of mentally ill veterans with psychedelics." October 25, 2026. https://politi.co/4idkGBF
    14. U.S. Food and Drug Administration. "FDA Seeks Public Input to Support Ibogaine Research." October 5, 2026. https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research
    15. Multidisciplinary Association for Psychedelic Studies (MAPS). "University of Miami's Gift of 1994 Ibogaine IND to HHS Sets a Standard for Open Science." August 25, 2026. https://maps.org/2026/08/25/university-of-miamis-gift/
    16. Colorado General Assembly. "HB26-1325 Natural Medicine." https://leg.colorado.gov/bills/hb26-1325
    17. U.S. Food and Drug Administration. "FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order." April 24, 2026. https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order
    18. The White House. "President Trump's Landmark Order Advances Breakthrough Mental Health Treatments — Delivering New Hope to Veterans." April 20, 2026. https://www.whitehouse.gov/releases/2026/04/president-trumps-landmark-order-advances-breakthrough-mental-health-treatments/
    19. HealingMaps. "Is Ibogaine Legal in the United States? A 2026 Guide to Federal, State, and Clinical Trial Access." April 21, 2026. https://healingmaps.com/is-ibogaine-legal-in-the-united-states-2026/